Paraganglioma, Extra-Adrenal - 25 Studies Found
Available |
: 18F-FDOPA PET in Neuroendocrine Tumours :
|
Active, not recruiting |
: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation :
: 2014-06-04 : Other: PET-CT |
Recruiting |
: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies :
: 2014-06-25 : Drug: DOTA-TOC PET/CT Single Gallium-68 DOTA-TOC PET/CT in patients with somatostatin receptor positive |
Active, not recruiting |
: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma :
: 2013-10-19 : Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |
Available |
: Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma :
: 2013-04-08 : Radiation: I-131 MIBG The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 |
Active, not recruiting |
: Dovitinib in Neuroendocrine Tumors :
: 2012-05-01 : Radiation: I-131 MIBG The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 |
Completed |
: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors :
|
Completed |
: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors :
: 2011-08-08 : Radiation: 131I-MIBG Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rock |
Available |
: Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma :
: 2011-06-13 : Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG) Therapeutic 131I-MIBG will be synthesized at Nuclear Di |